MDXG (mimedx.com) Market Value to Book Value Ratio

Official company branding of MiMedx Group Inc (MDXG)

MiMedx Group, Inc. (MDXG) dominates the regenerative therapy segment thanks to its exclusive PURION technology, which ensures steady demand for bio-implants. The market dynamics of the company's securities, where the indicator stands at 2.59, price in the dependence on the volume of surgeries and Medicare payments. However, legal disputes and regulatory uncertainty regarding the classification of human tissue products continue to hinder growth.

MDXG MiMedx Corp: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for MiMedx Group Inc (MDXG)

- price and consensus price forecast:
Stock Price MiMedx Group, Inc.|MDXG - Analyst Target Range
- market capitalization data:
Market Value MiMedx Group|MDXG - Full Business Value
- book capitalization data:
Book Value per Share MiMedx|MDXG - Accounting Value of Company|Market Capitalization to Book Value Ratio mimedx.com|MDXG - Company Total Assets
- debt and liquidity data:
Debt to Equity MiMedx Group, Inc.|MDXG - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MiMedx Group|MDXG - Company Total Debt|Debts to Book Capitalization MiMedx Group|MDXG - Company Long-Term Debts|Company Current Liabilities MiMedx
Initial company analysis:MiMedx Group, Inc. - MDXG
Original product of MiMedx Group

This indicator measures the market value premium over net assets, demonstrating the extent to which investors are willing to pay a premium for equity relative to its book value. Analyzing the market-to-book ratio allows for an assessment of the scaling potential of MiMedx Group, Inc. (MDXG), where the high margins of replicating regenerative technologies often justify a significant divergence of share prices from book value.

Main competitors

Market Capitalization to Book Value Ratio ASND (Ascendis Pharma A/S)|MDGL (madrigalpharma.com) - Market Value to Equity Ratio|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com (GPCR)|Rezolute (RZLT) - Market Cap to Net Assets Ratio|Market Value to Book Value LXRX (Lexicon Pharmaceuticals Inc)|MBX Bio - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Altimmune Pharma ALT|AARD (Aardvark Therapeutics Inc) - Market Capitalization to Book Value Ratio|sagimet.com (SGMT) - Market-to-Book Ratio|BIOA - Market Cap to Net Assets Ratio|Biomea Fusion Inc (BMEA) - Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio RDUS (Radius Pharmaceuticals)